Minimizing Risk of Nephrogenic systemic fibrosis in Cardiovascular Magnetic Resonance

Journal of Cardiovascular Magnetic Resonance

Volumn 14, Issue 1, 2012, Pages

  Reiter, Theresa ^a   Ritter, Oliver ^a   Prince, Martin R ^b   Nordbeck, Peter ^a   Wanner, Christoph ^a   Nagel, Eike ^c   Bauer, Wolfgang Rudolf ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CALCIPOTRIOL; CYCLOPHOSPHAMIDE; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IMATINIB; IMMUNOGLOBULIN; PENTOXIFYLLINE; PROCAINAMIDE; STEROID; THALIDOMIDE;

CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG STABILITY; EUROPE; EXTRACELLULAR FLUID; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; NEPHROGENIC SYSTEMIC FIBROSIS; NORTH AMERICA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATHOBIOCHEMISTRY; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT DURATION;

CARDIOVASCULAR DISEASES; CONTRAST MEDIA; GADOLINIUM; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING, CINE; NEPHROGENIC FIBROSING DERMOPATHY; RISK FACTORS; WORLD HEALTH;

EID: 84863207085     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-14-31     Document Type: Review

References (102)

1. The European Cardiovascular Magnetic Resonance Registry www.eurocmr-registry.com
2. Nephrogenic fibrosing dermopathy. Cowper SE, et al. Am J Dermatopathol. 2001 23 5 383 3 10.1097/00000372-200110000-00001 11801769 (Pubitemid 32938907)
3. Gadolinium and nephrogenic systemic fibrosis. Grobner T, Prischl FC, Kidney Int. 2007 72 3 260 4 10.1038/sj.ki.5002338 17507905 (Pubitemid 47172383)
4. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Idee JM, et al. Toxicology. 2008 248 2-3 77 8 18440117
5. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. Marckmann P, et al. J Am Soc Nephrol. 2006 17 9 2359 2 10.1681/ASN.2006060601 16885403 (Pubitemid 44300951)
6. Gadolinium-based contrast agents and nephrotoxicity. Morcos SK, Catheter Cardiovasc Interv. 2006 68 5 812 author reply 813 10.1002/ccd.20929 17039541 (Pubitemid 44721109)
7. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Thomsen HS, Morcos SK, Dawson P, Clin Radiol. 2006 61 11 905 6 10.1016/j.crad.2006.09.003 17018301 (Pubitemid 44464118)
8. NSF Registry www.pathmax.com/dermweb
9. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. Martin DR, et al. J Magn Reson Imaging. 2010 31 2 440 6 10.1002/jmri.22024 20099361
10. Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media. Rees O, Agarwal SK, Clin Radiol. 2010 65 8 636 1 10.1016/j.crad.2010.04.012 20599066
11. Incidence of Nephrogenic Systemic Fibrosis after Adoption of Restrictive Gadolinium-based Contrast Agent Guidelines. Wang Y, et al. Radiology. 2011 260 1 105 1 10.1148/radiol.11102340 21586680
12. Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging. Caravan P, et al. Inorg Chem. 2001 40 9 2170 6 10.1021/ic001117r 11304163 (Pubitemid 32884501)
13. Extracellular MRI Contrast Agents Based on Gadolinium Contrast Agents Springer Berlin, Heidelberg, Gries H, Krause IW, 2002 1 4
14. Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes. Hermann P, et al. Dalton Trans. 2008 23 3027 7 18521444
15. Kinetic Stabilities of Gadolinium(III) Chelates Used as MRI Contrast Agents. Brücher E, Top Curr Chem. 2002 221 103 2 10.1007/3-540-45733-X-4
16. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. Aime S, Caravan P, J Magn Reson Imaging. 2009 30 6 1259 7 10.1002/jmri.21969 19938038
17. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. Ersoy H, Rybicki FJ, J Magn Reson Imaging. 2007 26 5 1190 7 10.1002/jmri.21135 17969161 (Pubitemid 350058285)
18. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Frenzel T, et al. Invest Radiol. 2008 43 12 817 8 10.1097/RLI.0b013e3181852171 19002053
19. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. Idee JM, et al. J Magn Reson Imaging. 2009 30 6 1249 8 10.1002/jmri.21967 19938037
20. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Wedeking P, Kumar K, Tweedle MF, Magn Reson Imaging. 1992 10 4 641 8 10.1016/0730-725X(92)90016-S 1501535
21. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Port M, et al. Biometals. 2008 21 4 469 0 10.1007/s10534-008-9135-x 18344005
22. Incidence of Immediate Gadolinium Contrast Media Reactions. Prince MR, et al. Am J Roentgenol. 2011 196 2 138 3 10.2214/AJR.10.4885
23. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Joffe P, Thomsen HS, Meusel M, Acad Radiol. 1998 5 7 491 2 10.1016/S1076-6332(98)80191-8 9653466 (Pubitemid 28303906)
24. Stability of Gadolinium- based magnetic resonance imaging contrast agents in human serum at 37°C. Frenzel, 2008
25. The relationship between thermodynamics and the toxicity of gadolinium complexes. Cacheris WP, Quay SC, Rocklage SM, Magn Reson Imaging 1990 8 4 467 1 10.1016/0730-725X(90)90055-7 2118207 (Pubitemid 20321961)
26. Thermodynamics and NMR studies of DTPA-bis(methoxyethylamide) and its derivatives. Protonation and complexation with Ln(III). Imura H, Choppin GR, Cacheris WP, de Learie LA, Dunn TJ, White DH, Inorganica Chimica Acta. 1997 258 2 227 6 10.1016/S0020-1693(96)05522-3 (Pubitemid 127347156)
27. Synthesis, in vitro biological stability, and anti-HIV activity of 5-halo-6-alkoxy(or azido)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs to 3'-azido-3'-deoxythymidine (AZT). Kumar R, et al. J Med Chem. 1994 37 25 4297 6 10.1021/jm00051a006 7996541
28. Complexing mechanism of the lanthanide cations Eu3+, Gd3+, and Tb3+ with 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (dota)-characterization of three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence spectroscopy, and EXAFS. Moreau J, et al. Chemistry. 2004 10 20 5218 2 10.1002/chem.200400006 15372580
29. Synthesis and Physicochemical Characterization of a New Gadolinium Chelate: The Liver-Specific Magnetic Resonance Imaging Contrast Agent Gd-EOB-DTPA. Schmitt-Willich H, et al. Inorg Chem. 1999 38 6 1134 4 10.1021/ic981072i 11670895
30. Equilibrium and kinetic studies on complexes of 10-[2,3-dihydroxy-(1- hydroxymethyl)-propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate. Toth E, Kiraly R, Platzek J, Raduchel B, Brucher E, Inorganica Chimica Acta. 1996 249 2 191 9 10.1016/0020-1693(96)05094-3 (Pubitemid 126316470)
31. Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln=Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-carboxy-5,8,11- tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)] gadolinate(2-) in a mixture with its enantiomer. Uggeri F, Uggeri FAS, Anelli P, Botta M, Brocchetta M, De Haen C, Ermondi G, Grandi M, Paoli P, Inorg Chem. 1995 34 633 2 10.1021/ic00107a017
32. Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Haylor J, et al. Invest Radiol. 2010 45 9 507 2 10.1097/RLI.0b013e3181eb51f2 20697223
33. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Sadowski EA, et al. Radiology. 2007 243 1 148 7 10.1148/radiol.2431062144 17267695 (Pubitemid 46579705)
34. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Kuo PH, et al. Radiology. 2007 242 3 647 9 10.1148/radiol.2423061640 17213364
35. Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Edward M, et al. Radiology. 2010 256 3 735 3 10.1148/radiol.10091131 20663970
36. Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far? Morcos SK, Eur Radiol. 2011 21 3 496 0 10.1007/s00330-010-1951-z 20848109
37. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Tweedle MF, Wedeking P, Kumar K, Invest Radiol. 1995 30 6 372 0 10.1097/00004424-199506000-00008 7490190
38. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Varani J, et al. Invest Radiol. 2009 44 2 74 1 10.1097/RLI.0b013e31818f76b5 19077912
39. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. High WA, Ayers RA, Cowper SE, J Am Acad Dermatol. 2007 56 4 710 2 10.1016/j.jaad.2007.01.022 17289213 (Pubitemid 46400200)
40. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. High WA, et al. J Am Acad Dermatol. 2007 56 1 21 6 10.1016/j.jaad.2006.10.047 17097388 (Pubitemid 46017000)
41. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Mendoza FA, et al. Semin Arthritis Rheum. 2006 35 4 238 9 10.1016/j.semarthrit.2005.08.002 16461069 (Pubitemid 43185214)
42. Immunohistochemical aspects of the fibrogenic pathway in nephrogenic systemic fibrosis. Quatresooz P, et al. Appl Immunohistochem Mol Morphol. 2010 18 5 448 2 20485155
43. Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Bhagavathula N, et al. Invest Radiol. 2010 45 12 769 7 10.1097/RLI.0b013e3181e943d2 20714270
44. Decorin is significantly overexpressed in nephrogenic systemic fibrosis. Gambichler T, et al. Am J Clin Pathol. 2009 132 1 139 3 10.1309/AJCPGB55YDURJXZC 19864245
45. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Pietsch H, et al. Invest Radiol. 2011 46 1 48 6 10.1097/RLI.0b013e3181efd49a 20938346
46. Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Piera-Velazquez S, et al. Ann Rheum Dis. 2010 69 11 2017 3 10.1136/ard.2009.127761 20570839
47. The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. Kelly BC, et al. J Am Acad Dermatol. 2010 63 3 483 9 10.1016/j.jaad.2009.09.006 20708474
48. NFkappaB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Del Galdo F, et al. Ann Rheum Dis. 2010 69 11 2024 3 10.1136/ard.2010.134858 20959327
49. Effects of magnetic resonance imaging contrast agents on human umbilical vein endothelial cells and evaluation of magnetic resonance imaging contrast media-triggered transforming growth factor-beta induction in dermal fibroblasts (HSF) as a model for nephrogenic systemic fibrosis. Wiesinger B, et al. Invest Radiol. 2011 46 1 71 6 10.1097/RLI.0b013e31820218e9 21139503
50. Nephrogenic systemic fibrosis: possible association with a predisposing infection. Golding LP, Provenzale JM, AJR Am J Roentgenol. 2008 190 4 1069 5 10.2214/AJR.07.2884 18356457 (Pubitemid 351571527)
51. Impact of contrast enhanced MRI on lymphocyte DNA damage and serum visfatin level. Yildiz S, et al. Clin Biochem 2011 44 12 975 9 10.1016/j.clinbiochem.2011.05.005 21620817
52. Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Hope TA, et al. Radiology 2009 253 2 390 8 10.1148/radiol.2532090580 19789237
53. Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions. Schieren G, et al. Am J Kidney Dis 2010 55 6 1040 9 10.1053/j.ajkd.2010.01.021 20430497
54. Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation. Vakil V, et al. J Magn Reson Imaging 2009 30 6 1284 8 10.1002/jmri.21800 19937928
55. Gadolinium-promoted precipitation of calcium phosphate is associated with profibrotic activation of RAW 264.7 macrophages. Gou BD, et al. Toxicol In Vitro 2010 24 6 1743 9 10.1016/j.tiv.2010.05.004 20471468
56. Clinical and histological findings in nephrogenic systemic fibrosis. Cowper SE, Rabach M, Girardi M, Eur J Radiol. 2008 66 2 191 9 10.1016/j.ejrad.2008.01.016 18325705
57. NSF Registry, updated 2011 www.icnfdr.org
58. Nephrogenic fibrosing dermopathy: the first 6years. Cowper SE, Curr Opin Rheumatol. 2003 15 6 785 0 10.1097/00002281-200311000-00017 14569211 (Pubitemid 38156308)
59. Nephrogenic systemic fibrosis. Samtleben W, Radiologe. 2007 47 9 778 4 10.1007/s00117-007-1545-1 17717643 (Pubitemid 47459038)
60. Nephrogenic systemic fibrosis: an overview. Cowper SE, J Am Coll Radiol. 2008 5 1 23 8 10.1016/j.jacr.2007.08.013 18180005
61. Acute phase reaction to gadolinium-DTPA in dialysis patients. Steen H, et al. Nephrol Dial Transplant. 2009 24 4 1274 7 19042926
62. Anaphylaxis to radiographic contrast media. Brockow K, Ring J, Curr Opin Allergy Clin Immunol. 2011 11 4 326 1 10.1097/ACI.0b013e32834877c3 21659863
63. Risk factors for NSF: a literature review. Prince MR, et al. J Magn Reson Imaging. 2009 30 6 1298 8 10.1002/jmri.21973 19937930
64. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. Prince MR, Arnoldus C, Frisoli JK, J Magn Reson Imaging. 1996 6 1 162 6 10.1002/jmri.1880060129 8851422 (Pubitemid 126702459)
65. Incidence of nephrogenic systemic fibrosis at two large medical centers. Prince MR, et al. Radiology. 2008 248 3 807 6 10.1148/radiol.2483071863 18710976
66. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Deo A, Fogel M, Cowper SE, Clin J Am Soc Nephrol 2007 2 2 264 7 10.2215/CJN.03921106 17699423
67. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Collidge TA, et al. Radiology 2007 245 1 168 5 10.1148/radiol.2451070353 17704357 (Pubitemid 47417800)
68. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Kallen AJ, et al. Am J Kidney Dis. 2008 51 6 966 5 10.1053/j.ajkd.2007.12.036 18501784 (Pubitemid 351711602)
69. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Marckmann P, et al. Nephrol Dial Transplant. 2007 22 11 3174 8 10.1093/ndt/gfm261 17483196 (Pubitemid 350202540)
70. æ. FDA-GBCA and NSF Core Presentations, http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM196218.pdf. As seen on 1.Februar 2012
71. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Zou Z, Ma L, Indian J Dermatol. 2011 56 1 65 3 10.4103/0019-5154.77556 21572796
72. Nephrogenic fibrosing dermopathy in children. Auron A, Shao L, Warady BA, Pediatr Nephrol. 2006 21 9 1307 1 10.1007/s00467-006-0174-7 16821025 (Pubitemid 44203458)
73. Gadolinium-associated nephrogenic systemic fibrosis in a 9-year-old boy. Foss C, et al. Pediatr Dermatol. 2009 26 5 579 2 10.1111/j.1525-1470.2008.00802. x 19840315
74. Nephrogenic fibrosing dermopathy in pediatric patients. Jain SM, et al. Pediatr Nephrol. 2004 19 4 467 0 10.1007/s00467-003-1380-1 14872332 (Pubitemid 38477417)
75. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. Marckmann P, Eur J Radiol. 2008 66 2 187 0 10.1016/j.ejrad.2008.01.032 18328659
76. Removal of gadolinium by dialysis: review of different strategies and techniques. Silberzweig JI, Chung M, J Magn Reson Imaging. 2009 30 6 1347 9 10.1002/jmri.21981 19937933
77. Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Chung HJ, Chung KY, Br J Dermatol. 2004 150 3 596 7 10.1111/j.1365-2133.2003.05795.x 15030351 (Pubitemid 38446323)
78. Treatment of nephrogenic systemic fibrosis with Re-PUVA. Duffy KL, et al. J Am Acad Dermatol. 2008 59 2 Suppl 1 39 0 18625379
79. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Fretellier N, et al. Invest Radiol. 2011 46 2 85 3 10.1097/RLI.0b013e3181f54044 20938344
80. Acetazolamide therapy in meningeal involvement of nephrogenic systemic fibrosis. Geara AS, El-Imad B, El-Sayegh S, Intern Med J. 2010 40 12 4 5 10.1111/j.1445-5994.2010.02378.x 21260956
81. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Kay J, High WA, Arthritis Rheum. 2008 58 8 2543 8 10.1002/art.23696 18668587
82. Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis. Marckmann P, Nielsen AH, Sloth JJ, Nephrol Dial Transplant. 2008 23 10 3280 2 10.1093/ndt/gfn217 18436563
83. Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature. Mathur K, et al. J Clin Apher. 2008 23 4 144 0 10.1002/jca.20170 18633995
84. Transmetallation and gadolinium: Do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients? Panesar M, et al. Hemodialysis Int. 2010 14 3 289 4 10.1111/j.1542-4758.2010.00456.x
85. Imaging patients with kidney disease: how do we approach contrast-related toxicity? Perazella MA, Reilly RF, Am J Med Sci. 2011 341 3 215 1 10.1097/MAJ.0b013e3181f016e6 21139495
86. Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. Pieringer H, et al. Nephrol Dial Transplant 2007 22 10 3094 10.1093/ndt/gfm435 17602192 (Pubitemid 350093466)
87. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Richmond H, et al. Arch Dermatol 2007 143 8 1025 0 10.1001/archderm.143.8.1025 17709661 (Pubitemid 47296079)
88. Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase. Swaminathan S, et al. J Am Acad Dermatol. 2010 62 2 343 5 10.1016/j.jaad.2009.04.022 20115955
89. UV-A1 therapy for nephrogenic systemic fibrosis. Tran KT, et al. Arch Dermatol. 2009 145 10 1170 4 10.1001/archdermatol.2009.245 19841406
90. æ. U.S. Food and Drug Administration, www.fda.org, section drugs/drug safety
91. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Levey AS, et al. Ann Intern Med. 2003 139 2 137 7 12859163
92. European Medicines Agency EMA, Hauptinformationen für Bedienstete im Gesundheitswesen-Gadolinium- haltige Kontrastmittel und das Risiko für das Auftreten von nephrogenen systemischen Fibrosen (NSF) 2010 www.emea.org 22837922
93. European Medicines Agency, www.ema.europa.eu/ema/, key words: Gadolinium based contrast agents
94. æ. European Society of Urogenial Radiology, ESUR, 2010 www.esur.org
95. Quarter-Dose (0.025mmol/kg) Gadobenate Dimeglumine for Abdominal MRI in Patients at Risk for Nephrogenic Systemic Fibrosis: Preliminary Observations. De Campos ROP, et al. Am J Roentgenol. 2011 196 3 545 2 10.2214/AJR.10.4500
96. Comparison of half-dose and full-dose gadolinium MR contrast on the enhancement of bone and soft tissue tumors. Costelloe CM, et al. Skeletal Radiol. 2011 40 3 327 3 10.1007/s00256-010-1028-8 20862469
97. Low-dose contrast-enhanced time-resolved MR angiography at 3T: diagnostic accuracy for treatment planning and follow-up of vascular malformations. Anzidei M, et al. Clin Radiol. 2011 66 12 1181 2 10.1016/j.crad.2011.08.003 21899830
98. Low dose CE-MRA. Nael K, Moriarty JM, Finn JP, Eur J Radiol. 2011 80 1 2 8 10.1016/j.ejrad.2011.01.092 21458187
99. American College of Radiology-ACR, Subcommittee on MR Safety: ACR Manual on Contrast Media, Version 7 2010
100. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. Kramer CM, et al. J Cardiovasc Magn Reson. 2008 10 35 10.1186/1532-429X-10-35 18605997
101. Development of a universal dual-bolus injection scheme for the quantitative assessment of myocardial perfusion cardiovascular magnetic resonance. Ishida M, et al. J Cardiovasc Magn Reson. 2011 13 28 10.1186/1532-429X-13-28 21609423
102. Informatin on drugs to be found on www.fda.org (US Food and Drug administration), http://www.drugs.com/pro/vasovist.html (Drug Information Online), www.medicines.org.au/files/aspdotar.pdf (Medicines Information Australia); http://www.primovist.com/scripts/pages/en/primovist/index.php (Bayer Product Information); http://www.gadovist.ch/de/gadovist/dosierung-anwendung/ (Bayer Product Information)